紫杉醇联合表阿霉素治疗38例晚期乳腺癌的临床研究  

A Clinical Study of Paclitaxel Combined with Epirubicin in Treatment of Advanced Breast Cancer

作　　者：隋捷[1] 刘积良[1] 段寅[1] 

机构地区：[1]深圳市第二人民医院肿瘤科,广东深圳518035

出　　处：《河南肿瘤学杂志》2005年第1期28-29,共2页Henan Journal of Oncology

摘　　要：目的　观察紫杉醇 ,表阿霉素治疗晚期乳腺癌的疗效及其毒性。方法　病理明确的 3 8例晚期乳腺癌患者进入研究组 ,全组患者既往均行CMF/CAF方案化疗及常规放疗。治疗方法 :紫杉醇 15 0mg/m2 静脉输入 3h ,d1,表阿霉素 5 0mg/m2 静脉输注d1,2 1天重复 ,所有病人至少接受 2周期治疗。结果　经过 2周期化疗 ,完全缓解 3例 ( 7 9% ) ,部分缓解 18例 ( 4 7 4% ) ,14例病人稳定( 3 6 8% ) ,恶心、呕吐、骨髓抑制为主要不良反应 ,毒性相对较弱。结论　紫杉醇和表阿霉素治疗晚期乳腺癌缓解率高 。Objective To evaluate the efficacy and toxicity of Paclitaxel combined with Epirubicin in the patients with advanced breast cancer. Methods The patients with a histologic diagnosis of breast cancer were eligible. All patients were treated with CMF/CAF and conventional radiotherapy. The chemotherapy regimen was composed of 3_hour infusion of Paclitaxel 150 mg/m 2 d 1 and Epirubicin 50 mg/m 2 d 1 infusion. Every 21 days one cycles. All patients were received at least two cycles of treatment. Results After two cycles of chemotherapy ,3 obtained complete remission CR(7.9%). 18 obtained partial remission PR(47.4%), 14 had stable disease SD(36.8%).Nausea vomiting and myelosuppression were main side_effects. Toxicity was comparatively mild.Conclusions Data from the current study indicated that Paclitaxel combined with Epirubicin had moderate activity but comparatively mild toxicity for advanced breast cancer.

关 键 词：紫杉醇 表阿霉素 晚期乳腺癌 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤]